Kyverna says CAR-T manufacturing times can be cut through blood collection efficiencies 

Clin­i­cal-stage biotech Kyver­na Ther­a­peu­tics re­vealed fur­ther de­tails on how it can po­ten­tial­ly short­en pro­duc­tion time­lines for au­toim­mune CAR-Ts by us­ing its so-called “vein-to-vein” process.

Kyver­na, which has CAR-T as­sets un­der in­ves­ti­ga­tion in au­toim­mune dis­eases, on Wednes­day pub­lished de­tails in bioRx­iv for its pro­ce­dure called In­genui-T, which it de­vel­oped with cell and gene man­u­fac­tur­er El­e­vate­Bio, a col­lab­o­ra­tion pre­vi­ous­ly an­nounced in Sep­tem­ber last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.